| QUALITY |
|
| Year : 2013 | Volume
: 4
| Issue : 2 | Page : 144-147 |
|
|
Fraud and misconduct in clinical research: A concern
Ashwaria Gupta
Sr. CRA Group Head, Novartis Health Care Private Limited, Sandoz House, Worli, Mumbai, India
Correspondence Address:
Ashwaria Gupta
Sr. CRA Group Head, Novartis Health Care Private Limited, 5th Floor,Sandoz House, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2229-3485.111800
|
|
|
Fraud and misconduct in clinical research is widespread. Good clinical practice is a guideline adopted internationally as standard operating procedure for conduct of clinical research. Despite these guidelines being available, unavailability of internationally harmonized framework for managing research fraud and misconduct makes clinical research a highly vulnerable area to commit fraud. Fraud could be of various types and due to various reasons. Whatever the circumstances be, any fraud should be dealt with strictly and regulations should be in place to prevent its occurrence. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
